Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
about
Inventing new medicines: The FGF21 storyWeight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve studyAn update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial.Management of diabetes across the course of disease: minimizing obesity-associated complicationsInsulin detemir for the treatment of obese patients with type 2 diabetes.Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Long-acting basal insulin analogs: latest developments and clinical usefulness.Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.The role of insulin detemir in overweight type 2 diabetes management.Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational studyClinical experience with insulin detemir in patients with type 2 diabetes from the near East countries.Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.Insulin detemir: a review of its use in the management of diabetes mellitus.Weight regain in patients with symptoms of post-bariatric surgery hypoglycemia.Central Effects of Insulin Detemir on Feeding, Body Weight and Metabolism in Rats.The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Evaluation of the lack of anorectic effect of intracerebroventricular insulin in rats.
P2860
Q26823319-A6F3A3C6-571D-4405-818D-78C40DA1D1F5Q27026774-3923D95D-4F5A-441D-8453-A1A87B332A24Q33785184-61D350CA-7CDF-42C9-8955-CB3E3F84ECCFQ33902616-E64E8ACD-5C63-4026-A9AB-797E6083B50AQ34368524-BE1A5D81-EBFC-4B3E-8400-6994B91BAF82Q34468769-A3538D0E-149F-4022-9A74-3AAF18ED3047Q35060243-598CD678-AC2D-4905-A9FD-025DA62F14B6Q35150366-6ED88144-7E4C-45C8-AC18-A60BD45642EAQ35574560-3B34944A-F7FB-442E-9167-3FF7AD794196Q35703041-4970505E-551F-4814-A2DC-AF5CE1EC9644Q35769593-B212E15D-4EE3-4567-8793-0C8A5796E73EQ36334638-183056E0-5CB7-4AAE-BEB2-CECBE5F0C7E3Q36449523-C9165C45-EC93-4ED7-8219-E631F807EAC0Q36515474-ABDBD3E2-9622-4012-9694-032DDF5F878BQ36947990-2666E02A-92DE-469F-B90D-ADAE75B2D4A4Q37022851-31BDFFC1-8F7D-4A9A-AB90-AFD05A2367FDQ37199318-A01320E7-C9A2-4E47-85A0-83AA4816B6D6Q37226372-A4678B86-BCA9-4A90-A22A-6AE1DDE732FEQ37248234-917CD11B-C172-4BE0-A63D-972727188965Q37331162-90A3717D-B50E-4732-89D4-791FBBCC306EQ37365411-015A6DC0-D6EF-42E4-961D-AC64B7C48213Q37468419-2F905060-E465-40C5-898D-89C0F47381EDQ37893971-88045E7A-533D-4805-80F8-7C9981CBF67CQ37972941-6F39E434-5FA9-499A-B840-9B1977D09F74Q38056540-006652C3-A769-43B9-8434-C9E5D39C141DQ38636904-8946C20D-C798-4739-8E6C-B9AF585F5374Q38673291-1A97AD82-40A5-422D-AE31-AAC09E615898Q39109051-387884B7-E365-45A7-A24E-60D0010CB1BAQ39404106-7F54B59E-2954-4690-B3B8-D92278D0A8F6Q42157719-82D3D6B1-5AF5-4702-87A6-01B9481A198BQ42329441-0CC5FDDC-8AFE-42B9-B4A1-730A849F911CQ43012919-252209FB-CBE6-41FC-AE24-380337A2AE31Q46959407-7E5B4FE2-FEE7-40D1-901E-517D8D849508Q47175820-932DABDB-C3D5-474C-96B0-31B474ED0EDAQ48422314-7EB28FD7-B95E-4E5C-95A5-4A1583CC8E34
P2860
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@ast
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@en
type
label
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@ast
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@en
prefLabel
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@ast
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@en
P2860
P1476
Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
@en
P2093
Hermansen K
P2860
P304
P356
10.1111/J.1463-1326.2006.00665.X
P577
2007-05-01T00:00:00Z